Comparative efficacy of subcutaneous and intravenous infliximab and vedolizumab for maintenance treatment of TNF-naive adult patients with inflammatory bowel disease: A systematic literature review and network meta-analysis. | 2024 | Digestive Diseases and Sciences |
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: A systematic review and network meta-analysis. | 2023 | International Journal of Clinical Pharmacy |
Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. | 2023 | BMC Gastroenterology |
Vedolizumab for induction and maintenance of remission in Crohn's disease. | 2023 | The Cochrane Database of Systematic Reviews |
An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis. | 2023 | PLoS One |
Systematic literature review of real-world evidence on dose escalation and treatment switching in ulcerative colitis. | 2023 | ClinicoEconomics and Outcomes Research |
Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: A systematic review and meta-analysis. | 2023 | Therapeutic Advances in Gastroenterology |
Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta analysis of randomized controlled trials. | 2023 | Experimental and Therapeutic Medicine |
Dose escalation patterns of advanced therapies in Crohn's disease and ulcerative colitis: A systematic literature review. | 2023 | Advances in Therapy |
The efficacy and safety of biologic drugs in the treatment of moderate-severe Crohn's disease: A systematic review. | 2023 | Pharmaceuticals |
Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology. | 2023 | Digestive and Liver Disease |
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: A systematic review and network meta-analysis. | 2022 | International Journal of Clinical Pharmacy |
The effect of pregnancy and inflammatory bowel disease on the pharmacokinetics of drugs related to inflammatory bowel disease-a systematic literature review. | 2022 | Pharmaceutics |
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. | 2022 | BMC Gastroenterology |
Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: Systematic review and network meta-analysis of randomized controlled trials. | 2022 | Inflammatory Bowel Diseases |
Vedolizumab for perianal fistulizing Crohn’s disease: Systematic review and meta-analysis. | 2022 | Intestinal Research |
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease-a systematic review with meta-analysis. | 2022 | Digestive and Liver Disease |
Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Medicine |
Real-world effectiveness of vedolizumab dose escalation in patients with inflammatory bowel disease: A systematic literature review. | 2022 | Crohn's & Colitis 360 |
Vedolizumab for perianal fistulizing Crohn's disease: Systematic review and meta-analysis. | 2022 | Intestinal Research |
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: A network meta-analysis. | 2021 | Expert Review of Gastroenterology & Hepatology |
Systematic review and network meta-analysis: Comparative efficacy and safety of biosimilars, biologics and JAK1 inhibitors for active Crohn disease. | 2021 | Frontiers in Pharmacology |
Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
Biologics for inflammatory bowel disease and their safety in pregnancy: A systematic review and meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis. | 2020 | Clinical Gastroenterology and Hepatology |
Safety of vedolizumab in liver transplant recipients: A systematic review. | 2019 | United European Gastroenterology Journal |
Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: A systematic review. | 2019 | Journal of Crohn’s and Colitis |
Systematic review with meta‐analysis: Association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. | 2019 | Alimentary Pharmacology & Therapeutics |
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: A systematic review with pool analysis. | 2019 | Scandinavian Journal of Gastroenterology |
Ulcerative colitis-treatment with biologicals. | 2019 | Revista da Associação Médica Brasileira |
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. | 2019 | United European Gastroenterology Journal |